Education
About Us
Working with TipRanks
Follow Us
Cel-sci (CVM)
:CVM
Top Page
Cel-Sci
(NYSE MKT:CVM)
32Underperform
Cel-Sci (CVM) vs. S&P 500 (SPY)
Market Cap
$23.31M
Dividend YieldN/A
Average Volume (3M)992.05K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue GrowthN/A
EPS Growth30.96%
CountryUS
Employees43
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.47
Shares Outstanding77,211,540
10 Day Avg. Volume649,557
30 Day Avg. Volume992,046
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cel-Sci Business Overview & Revenue Model
Company DescriptionCEL-SCI Corporation is a biotechnology company focused on the research and development of immunotherapy products for the treatment of cancer and other diseases. The company operates primarily in the biotechnology and pharmaceutical sectors, with its core product being Multikine, an investigational immunotherapy designed to harness the body's natural immune system to fight cancer. CEL-SCI is headquartered in Vienna, Virginia, and is committed to advancing healthcare through innovative immunotherapy solutions.
How the Company Makes MoneyCEL-SCI Corporation primarily makes money through securing funding for its research and development activities. The company generates revenue from a combination of sources, including sales of its investigational products upon regulatory approval, research grants, and strategic partnerships with other pharmaceutical and biotechnology companies. Given its focus on Multikine, a significant portion of its revenue model is based on the successful development, approval, and commercialization of this product. Additionally, CEL-SCI may engage in licensing agreements or collaboration arrangements that provide financial resources and support for ongoing and future projects. The company’s earnings are heavily influenced by its ability to achieve clinical milestones, secure regulatory approvals, and establish commercial partnerships.
Cel-Sci Financial Statement Overview
Summary
Cel-Sci is struggling financially, characterized by a lack of revenue generation, high operational losses, and dependency on external financing. The company's financial health is concerning, with persistent negative cash flows and significant debt levels posing risks to its sustainability. Strategic changes are needed to improve revenue and manage costs effectively to stabilize its financial position.Income Statement
Cel-Sci has consistently reported zero revenue over the past years, indicating a lack of product commercialization or sales. The gross profit and net income remain negative, reflecting ongoing operational losses and high costs relative to revenue. The company also faces negative EBIT and EBITDA margins, highlighting inefficiencies and challenges in achieving profitability.10
Very Negative
Balance Sheet
The company's financial leverage is relatively high, as indicated by the debt-to-equity ratio, due to significant debt levels compared to equity. Stockholders' equity has been declining, with the equity ratio showing a downward trend. This reflects potential balance sheet risks, including financial instability and limited flexibility for future financing.20
Very Negative
Cash Flow
Cel-Sci is experiencing negative operating and free cash flows, suggesting challenges in generating cash from operations. The company relies heavily on financing activities to fund operations, which may not be sustainable in the long term. The operating cash flow to net income ratio is unfavorable, indicating inefficiencies in cash generation relative to reported losses.15
Very Negative
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 558.66K | Gross Profit |
| -2.96M | -3.97M | -3.96M | -3.88M | -499.00K | 540.82K | EBIT |
| -26.76M | -26.35M | -31.48M | -36.06M | -36.19M | -28.99M | EBITDA |
| -22.61M | -22.21M | -27.56M | -31.74M | -33.96M | -26.83M | Net Income Common Stockholders |
| -27.28M | -26.92M | ― | -38.27M | -39.19M | -32.22M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.61M | 4.74M | 4.15M | 22.67M | 42.21M | 15.51M | Total Assets |
| 25.70M | 26.99M | 30.53M | 50.52M | 75.87M | 40.54M | Total Debt |
| 11.09M | 11.62M | 13.57M | 15.30M | 15.97M | 13.94M | Net Debt |
| 6.47M | 6.88M | 9.43M | -7.37M | -20.09M | -1.57M | Total Liabilities |
| 14.39M | 14.12M | 17.31M | 18.36M | 19.34M | 20.81M | Stockholders Equity |
| 11.31M | 12.87M | 13.21M | 32.16M | 56.53M | 19.73M |
| Cash Flow | Free Cash Flow | ||||
| -18.10M | -18.91M | -23.22M | -18.90M | -27.83M | -17.97M | Operating Cash Flow |
| -18.06M | -18.81M | -22.85M | -18.24M | -18.79M | -15.28M | Investing Cash Flow |
| -76.18K | -108.09K | -372.26K | 5.49M | -15.18M | -2.69M | Financing Cash Flow |
| 19.51M | 19.51M | 4.69M | -638.43K | 54.52M | 25.04M |
Cel-Sci Technical Analysis
Negative
0.30
Price Trends
0.39
Negative
0.55
Negative
0.86
Negative
Market Momentum
-0.03
Positive
36.17
Neutral
19.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVM, the sentiment is Negative. The current price of 0.3 is below the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.39, and below the 200-day MA of 0.86, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.17 is Neutral, neither overbought nor oversold. The STOCH value of 19.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVM.
Cel-Sci Risk Analysis
Cel-Sci disclosed 39 risk factors in its most recent earnings report. Cel-Sci reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cel-Sci Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $74.97M | ― | -138.69% | ― | 183.05% | -83.05% | |
51 Neutral | $318.22M | ― | -136.87% | ― | ― | 21.19% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
46 Neutral | $265.13M | ― | -33.88% | ― | ― | -22.66% | |
44 Neutral | $118.14M | ― | -53.54% | ― | 145.37% | 57.01% | |
33 Underperform | $70.39M | ― | -106.64% | ― | -76.18% | 40.70% | |
32 Underperform | $23.31M | ― | -227.76% | ― | ― | 30.96% |
* Healthcare Sector Average
Performance Comparison
CVM
Cel-Sci
0.30
-1.81
-85.78%
INO
Inovio Pharmaceuticals
1.93
-8.88
-82.15%
VSTM
Verastem
7.21
-3.29
-31.33%
TNXP
Tonix Pharma
13.64
-1,049.72
-98.72%
ADAP
Adaptimmune Therapeutics
0.45
-1.01
-69.18%
AVIR
Atea Pharmaceuticals
3.06
-0.79
-20.52%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.